ORIGINAL ARTICLE
Hepatocellular carcinoma – clinicopathological characteristics, survival, and expression of various histologic molecular markers
1
University Clinic for Gastroenterohepatology, Skopje, Republic of North Macedonia
2
Institute of Pathology, Faculty of Medicine, Skopje, Republic of North Macedonia
3
Department of Epidemiology and Biostatistics, Faculty of Medicine, Skopje, Republic of North Macedonia
Submission date: 2018-07-13
Final revision date: 2019-05-28
Acceptance date: 2019-06-14
Publication date: 2020-03-06
Pol J Pathol 2019;70(4):269-276
KEYWORDS
TOPICS
ABSTRACT
The aim of this study was to make a clinical characterisation of patients with hepatocellular carcinoma and to investigate the expression of a set of molecular markers in patients from the Republic of North Macedonia. We analysed 60 patients for clinicopathologic factors, and we investigated tumour tissue and surrounding liver tissue for immunoexpression of E-cadherin, β-catenin, cyclin D1, and p53. Infection with hepatitis virus B and C (p < 0.001), tumour dimension (p < 0.001), vascular invasion (p < 0.002), and tumour differentiation (p < 0.021) significantly influenced the survival of the patients. E-cadherin and β-catenin expression reduction and cyclin D1 and p53 overexpression were significantly higher in the tumour than in the non-tumour tissue (p < 0.001; p < 0.001; p = 0.001; p < 0.001, respectively). No significant correlation was found between clinicopathological characteristics and the analysed molecules nor between the molecules themselves. The immunoexpression of E-cadherin, β-catenin, cyclin D1, and p53 was not related to the tumour aggressiveness and prognosis. However, their significantly higher expression in HCC tissue compared to that in non-tumour tissue indicate their important role in hepatocarcinogenesis. The clinicopathological characteristics of the neoplasm remain highly predictive factors for the survival of the patients.
REFERENCES (36)
2.
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74-108.
3.
Altekruse SF, Henley SJ, Cucinelli JE, et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014; 109: 542-553.
4.
Huang W, You L, Yang S, et al. S-1 for treatment of advanced hepatocellular carcinoma: a systematic review of the literature. Contemp Oncol (Pozn) 2017; 21: 16-20.
5.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
6.
Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma.World J Gastroenterol 2002; 8: 385-392.
7.
AJCC cancer staging manual. 8th edition. Amin MB, Edge SB, Green F, et al. (eds). Springer, Switzerland 2017.
8.
Hirohashi S, Ishak KG, Kojiro M, et al. Tumours of the liver and intrahepatic bile ducts. In: WHO classification of tumours of the digestive system. Hamilton S, Aaltonen LA (eds). 4th ed. IARCPress, Lyon, France 2010; 195-263.
9.
Schlageter M, Terracciano LM, D’Angelo S, et al. Histopathology of hepatocellular carcinoma. World J Gastroenterol 2014; 20: 15955-15964.
10.
Ng I. Molecular pathogenesis of hepatocellular carcinoma. Hong Kong J Radiol 2012; 15 (Suppl): S23-S28.
11.
Terry K, Copur SM. Molecular targeted therapy of hepatocellular carcinoma. JCT 2013; 4: 426-439.
12.
Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010; 15 (suppl 4): 14-22.
13.
Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 2004; 11: 383-393.
14.
Avadanei E, Giusca S, Negura L, Caruntu I. Single nucleotide polymorphisms of XRCC3 gene in hepatocellular carcinoma – relationship with clinicopathological features. Pol J Pathol 2018; 69: 73-78.
15.
Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005.
16.
Kasprzak A, Rogacki K, Adamek A, et al. Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma. Arch Med Sci 2017; 13: 1269-1280.
17.
Zhai B, Yan HX, Liu SQ, et al. Reduced expression of E-cadherin/catenins complex in hepatocellular carcinomas. World J Gastroenterol 2008; 14: 5665-5673.
18.
Yap AS. The morphogenetic role of cadherin cell adhesion molecules in human cancer: a thematic review. Cancer Invest 1998; 16: 252-261.
19.
Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483-1487.
20.
Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993; 9: 317-321.
21.
Wei Y, Van Nhieu JT, Prigent S, et al. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 2002; 36: 692-701.
22.
Huang H, Fujii H, Sankila A, et al. β-Catenin mutations are frequent in human hepatocellular carcinoma associated with hepatitis C virus infection. Am J Pathol 1999; 155: 1795-1801.
24.
Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002; 8: 450-456.
25.
Chen J, Zhao J, Ma R, et al. Prognostic significance of E-cadherin expression in hepatocellular carcinoma: a meta-analysis. PLoS ONE 2014; 9: e103952.
26.
Endo K, Ueda T, Ueyama J, et al. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients’ survival. Hum Pathol 2000; 31: 558-565.
27.
Kato J, Matsushime H, Hiebert SW, et al. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993; 7: 331-342.
28.
Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999; 96: 5522-5527.
29.
Lim SC, Lee MS. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep 2002; 9: 915-928.
30.
Ueta T, Ikeguchi M, Hirooka Y, et al. Beta-catenin and cyclin D1 expression in human hepatocellular carcinoma. Oncol Rep 2002; 9: 1197-1203.
31.
Deane NG, Parker MA, Aramandla R, et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 2001; 61: 5389-5395.
32.
Qu K, Wang Z, Fan H, et al. MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma. Cell Death Dis 2017; 8: e2603.
33.
Lu JW, Lin, YM, Chang JG, et al. Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma. Med Oncol 2013; 30: 379.
34.
Qi LN, Bai T, Chen ZS, et al. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China: role of chronic hepatitis B virus infection and aflatoxin B1 exposure. Liver Int 2015; 35: 999-1009.
35.
Jablkowski M, Bocian A, Bialkowska J, et al. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma. J Exp Clin Cancer Res 2005; 24: 117-125.
36.
Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997; 15: 1179-1189.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
